The global biosimilars market is on course to nearly triple in size over the next decade, reaching $70.79 billion by 2036, up from $26.58 billion in 2025 — a compound annual growth rate of 9.4 percent, according to biosimilars market data published by MarketsandMarkets in its latest exclusive industry report. The numbers land at a moment when healthcare systems worldwide are under acute pressure to cut drug costs without sacrificing clinical outcomes — and biosimilars are increasingly the lever regulators and payers are reaching for first. This is also a moment worth watching alongside the broader health-tech investment wave; as we noted in our coverage of AI-guided therapy, capital is flooding into treatments that can demonstrably reduce the cost burden of complex chronic disease.
Biosimilars are biological medicines that are highly similar to already-approved reference biologics — think complex protein-based drugs like monoclonal antibodies and insulin analogs — but sold at significantly lower price points once the originator’s patent protection expires. Unlike generic small-molecule drugs, biosimilars require sophisticated manufacturing processes and rigorous clinical comparability studies, which is why the market has taken longer to mature than traditional generics. But the infrastructure is catching up fast, and a looming wave of patent expirations on blockbuster biologics is set to flood the pipeline with new entrants.
Patent Cliffs, Pipeline Pressure, and Who’s Winning
The single biggest structural force driving this market is the so-called patent cliff — the expiration of exclusivity protections on some of the world’s best-selling biologics, including treatments for rheumatoid arthritis, cancer, and diabetes. As those windows close, biosimilar manufacturers gain legal access to compete directly. The MarketsandMarkets report identifies monoclonal antibodies as the leading product segment, a category that has already seen fierce biosimilar competition for drugs like adalimumab, the active ingredient in AbbVie’s Humira, which lost U.S. exclusivity in 2023 and triggered one of the largest biosimilar launches in history.
Geographically, North America currently holds the largest share of the biosimilars market, driven by regulatory clarity from the FDA and aggressive formulary adoption by pharmacy benefit managers and insurers pushing to reduce specialty drug spend. Europe, which has operated a mature biosimilars framework through the European Medicines Agency for nearly two decades, remains a critical proving ground for manufacturers looking to establish safety and efficacy track records before entering the U.S. market. The Asia-Pacific region, meanwhile, is flagged in the report as the fastest-growing geography, propelled by expanding healthcare access, government procurement programs, and domestic manufacturing investment in countries including India, South Korea, and China.
Regulatory Momentum and the Road to Interchangeability
Regulatory evolution is as important as market size when assessing where this industry goes next. In the United States, the FDA’s interchangeability designation — which allows pharmacists to substitute a biosimilar for a reference biologic without physician intervention, just as they do with traditional generics — has been a critical unlock. Several biosimilars have now achieved that status, and the designation is widely expected to accelerate adoption at the pharmacy counter level, where formulary inertia has historically slowed uptake even when payers wanted the cheaper option.
The competitive landscape is densely populated. Key players identified in the MarketsandMarkets report include Pfizer, Novartis’s Sandoz division, Amgen, Samsung Bioepis, and Biocon Biologics, among others. The race is not purely about price — manufacturing reliability, physician familiarity, and patient support programs are increasingly differentiating factors as more biosimilars compete for the same reference drug. With over $70 billion at stake by the mid-2030s, the companies that build the most defensible manufacturing and regulatory track records in the next three to four years are likely to define who controls the market when the next generation of biologic patents expires. The window to establish that position is narrowing quickly.
